BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18159826)

  • 1. [Tumor makrers in cervical cancer].
    Markowska J
    Ginekol Pol; 2007 Sep; 78(9):715-8. PubMed ID: 18159826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
    Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
    Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
    Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
    Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
    Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
    Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
    Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
    Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
    Gadducci A; Tana R; Fanucchi A; Genazzani AR
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
    Bedkowska GE; Lawicki S; Szmitkowski M
    Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
    Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
    Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
    Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
    Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
    Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.
    Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
    Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K
    Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
    Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
    BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer.
    Guo S; Yang B; Liu H; Li Y; Li S; Ma L; Liu J; Guo W
    J Cancer Res Ther; 2017; 13(4):689-692. PubMed ID: 28901315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between serum cytokines and progression of breast cancer in Chinese population.
    Wang H; Yang X
    Medicine (Baltimore); 2017 Dec; 96(49):e8840. PubMed ID: 29245248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
    Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
    Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.